Close Menu

NEW YORK ─ Luminex on Wednesday announced that it has received a $683,500 award from the US Department of Health and Human Services' Biomedical Advanced Research and Development Authority (BARDA) to support the enhancement of its xMap SARS-CoV-2 Multi-Antigen IgG Assay.

The Austin, Texas-based diagnostic company said it seeks to develop a test that identifies prior infection and assesses the neutralizing activity of the immune response.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.